These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 24816152)

  • 21. Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study.
    Lakhani NJ; Chow LQM; Gainor JF; LoRusso P; Lee KW; Chung HC; Lee J; Bang YJ; Hodi FS; Kim WS; Santana-Davila R; Fanning P; Squifflet P; Jin F; Kuo TC; Wan HI; Pons J; Randolph SS; Messersmith WA
    Lancet Oncol; 2021 Dec; 22(12):1740-1751. PubMed ID: 34793719
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial.
    Tap WD; Jones RL; Van Tine BA; Chmielowski B; Elias AD; Adkins D; Agulnik M; Cooney MM; Livingston MB; Pennock G; Hameed MR; Shah GD; Qin A; Shahir A; Cronier DM; Ilaria R; Conti I; Cosaert J; Schwartz GK
    Lancet; 2016 Jul; 388(10043):488-97. PubMed ID: 27291997
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Icrucumab, a fully human monoclonal antibody against the vascular endothelial growth factor receptor-1, in the treatment of patients with advanced solid malignancies: a Phase 1 study.
    LoRusso PM; Krishnamurthi S; Youssoufian H; Hall N; Fox F; Dontabhaktuni A; Grebennik D; Remick S
    Invest New Drugs; 2014 Apr; 32(2):303-11. PubMed ID: 23903897
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase I dose-finding study of monotherapy with atezolizumab, an engineered immunoglobulin monoclonal antibody targeting PD-L1, in Japanese patients with advanced solid tumors.
    Mizugaki H; Yamamoto N; Murakami H; Kenmotsu H; Fujiwara Y; Ishida Y; Kawakami T; Takahashi T
    Invest New Drugs; 2016 Oct; 34(5):596-603. PubMed ID: 27363843
    [TBL] [Abstract][Full Text] [Related]  

  • 25. LY3022855, an anti-colony stimulating factor-1 receptor (CSF-1R) monoclonal antibody, in patients with advanced solid tumors refractory to standard therapy: phase 1 dose-escalation trial.
    Dowlati A; Harvey RD; Carvajal RD; Hamid O; Klempner SJ; Kauh JSW; Peterson DA; Yu D; Chapman SC; Szpurka AM; Carlsen M; Quinlan T; Wesolowski R
    Invest New Drugs; 2021 Aug; 39(4):1057-1071. PubMed ID: 33624233
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A phase 1 study of anti-TGFβ receptor type-II monoclonal antibody LY3022859 in patients with advanced solid tumors.
    Tolcher AW; Berlin JD; Cosaert J; Kauh J; Chan E; Piha-Paul SA; Amaya A; Tang S; Driscoll K; Kimbung R; Kambhampati SR; Gueorguieva I; Hong DS
    Cancer Chemother Pharmacol; 2017 Apr; 79(4):673-680. PubMed ID: 28280971
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A phase I escalating single-dose and weekly fixed-dose study of cetuximab pharmacokinetics in Japanese patients with solid tumors.
    Shirao K; Yoshino T; Boku N; Kato K; Hamaguchi T; Yasui H; Yamamoto N; Tanigawara Y; Nolting A; Yoshino S
    Cancer Chemother Pharmacol; 2009 Aug; 64(3):557-64. PubMed ID: 19169687
    [TBL] [Abstract][Full Text] [Related]  

  • 28. First-in-Human Phase I, Dose-Escalation and -Expansion Study of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, in Patients With Advanced Solid Tumors.
    Strickler JH; Weekes CD; Nemunaitis J; Ramanathan RK; Heist RS; Morgensztern D; Angevin E; Bauer TM; Yue H; Motwani M; Parikh A; Reilly EB; Afar D; Naumovski L; Kelly K
    J Clin Oncol; 2018 Nov; 36(33):3298-3306. PubMed ID: 30285518
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase 1 study of ganitumab (AMG 479), a fully human monoclonal antibody against the insulin-like growth factor receptor type I (IGF1R), in Japanese patients with advanced solid tumors.
    Murakami H; Doi T; Yamamoto N; Watanabe J; Boku N; Fuse N; Yoshino T; Ohtsu A; Otani S; Shibayama K; Takubo T; Loh E
    Cancer Chemother Pharmacol; 2012 Sep; 70(3):407-14. PubMed ID: 22810805
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety, efficacy and pharmacokinetics of neratinib (HKI-272) in Japanese patients with advanced solid tumors: a Phase 1 dose-escalation study.
    Ito Y; Suenaga M; Hatake K; Takahashi S; Yokoyama M; Onozawa Y; Yamazaki K; Hironaka S; Hashigami K; Hasegawa H; Takenaka N; Boku N
    Jpn J Clin Oncol; 2012 Apr; 42(4):278-86. PubMed ID: 22371427
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Randomized phase II study of the PDGFRα antibody olaratumab plus liposomal doxorubicin versus liposomal doxorubicin alone in patients with platinum-refractory or platinum-resistant advanced ovarian cancer.
    McGuire WP; Penson RT; Gore M; Herraez AC; Peterson P; Shahir A; Ilaria R
    BMC Cancer; 2018 Dec; 18(1):1292. PubMed ID: 30591028
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase 1 study of conatumumab, a pro-apoptotic death receptor 5 agonist antibody, in Japanese patients with advanced solid tumors.
    Doi T; Murakami H; Ohtsu A; Fuse N; Yoshino T; Yamamoto N; Boku N; Onozawa Y; Hsu CP; Gorski KS; Friberg G; Kawaguchi T; Sasaki T
    Cancer Chemother Pharmacol; 2011 Sep; 68(3):733-41. PubMed ID: 21161528
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A first-in-human phase 1a study of the bispecific anti-DLL4/anti-VEGF antibody navicixizumab (OMP-305B83) in patients with previously treated solid tumors.
    Jimeno A; Moore KN; Gordon M; Chugh R; Diamond JR; Aljumaily R; Mendelson D; Kapoun AM; Xu L; Stagg R; Smith DC
    Invest New Drugs; 2019 Jun; 37(3):461-472. PubMed ID: 30229512
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety, pharmacokinetics, and antitumor activity of the anti-CEACAM5-DM4 antibody-drug conjugate tusamitamab ravtansine (SAR408701) in patients with advanced solid tumors: first-in-human dose-escalation study.
    Gazzah A; Bedard PL; Hierro C; Kang YK; Abdul Razak A; Ryu MH; Demers B; Fagniez N; Henry C; Hospitel M; Soria JC; Tabernero J
    Ann Oncol; 2022 Apr; 33(4):416-425. PubMed ID: 35026412
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study.
    Antonia S; Goldberg SB; Balmanoukian A; Chaft JE; Sanborn RE; Gupta A; Narwal R; Steele K; Gu Y; Karakunnel JJ; Rizvi NA
    Lancet Oncol; 2016 Mar; 17(3):299-308. PubMed ID: 26858122
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase 1 dose escalation study of seribantumab (MM-121), an anti-HER3 monoclonal antibody, in patients with advanced solid tumors.
    Denlinger CS; Keedy VL; Moyo V; MacBeath G; Shapiro GI
    Invest New Drugs; 2021 Dec; 39(6):1604-1612. PubMed ID: 34250553
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial.
    Choueiri TK; Larkin J; Oya M; Thistlethwaite F; Martignoni M; Nathan P; Powles T; McDermott D; Robbins PB; Chism DD; Cho D; Atkins MB; Gordon MS; Gupta S; Uemura H; Tomita Y; Compagnoni A; Fowst C; di Pietro A; Rini BI
    Lancet Oncol; 2018 Apr; 19(4):451-460. PubMed ID: 29530667
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase 1 trial of avelumab (anti-PD-L1) in Japanese patients with advanced solid tumors, including dose expansion in patients with gastric or gastroesophageal junction cancer: the JAVELIN Solid Tumor JPN trial.
    Doi T; Iwasa S; Muro K; Satoh T; Hironaka S; Esaki T; Nishina T; Hara H; Machida N; Komatsu Y; Shimada Y; Otsu S; Shimizu S; Watanabe M
    Gastric Cancer; 2019 Jul; 22(4):817-827. PubMed ID: 30515672
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A phase I pharmacokinetic and pharmacodynamic study of dalotuzumab (MK-0646), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in patients with advanced solid tumors.
    Atzori F; Tabernero J; Cervantes A; Prudkin L; Andreu J; Rodríguez-Braun E; Domingo A; Guijarro J; Gamez C; Rodon J; Di Cosimo S; Brown H; Clark J; Hardwick JS; Beckman RA; Hanley WD; Hsu K; Calvo E; Roselló S; Langdon RB; Baselga J
    Clin Cancer Res; 2011 Oct; 17(19):6304-12. PubMed ID: 21810918
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase II study of olaratumab with paclitaxel/carboplatin (P/C) or P/C alone in previously untreated advanced NSCLC.
    Gerber DE; Swanson P; Lopez-Chavez A; Wong L; Dowlati A; Pennell NA; Cronier DM; Qin A; Ilaria R; Cosaert J; Shahir A; Baggstrom MQ
    Lung Cancer; 2017 Sep; 111():108-115. PubMed ID: 28838379
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.